T. cruzi OligoC-TesT: A Simplified and Standardized Polymerase Chain Reaction Format for Diagnosis of Chagas Disease by Deborggraeve, Stijn et al.
T. cruzi OligoC-TesT: A Simplified and Standardized

















1Department of Parasitology, Institute of Tropical Medicine Antwerp, Antwerp, Belgium, 2Laboratory of Medicinal Chemistry, Rega Institute for Medicinal Research,
Katholieke Universiteit Leuven, Leuven, Belgium, 3Program of Molecular and Cellular Biology, Faculty of Medicine, University of Chile, Santiago, Chile, 4Coris BioConcept,
Gembloux, Belgium
Abstract
Background: PCR has evolved into one of the most promising tools for T. cruzi detection in the diagnosis and control of
Chagas disease. However, general use of the technique is hampered by its complexity and the lack of standardization.
Methodology: We here present the development and phase I evaluation of the T. cruzi OligoC-TesT, a simple and
standardized dipstick format for detection of PCR amplified T. cruzi DNA. The specificity and sensitivity of the assay were
evaluated on blood samples from 60 Chagas non-endemic and 48 endemic control persons and on biological samples from
33 patients, 7 reservoir animals, and 14 vectors collected in Chile.
Principal Findings: The lower detection limits of the T. cruzi OligoC-TesT were 1 pg and 1 to 10 fg of DNA from T. cruzi
lineage I and II, respectively. The test showed a specificity of 100% (95% confidence interval [CI]: 96.6%–100%) on the
control samples and a sensitivity of 93.9% (95% CI: 80.4%–98.3%), 100% (95% CI: 64.6%–100%), and 100% (95% CI: 78.5%–
100%) on the human, rodent, and vector samples, respectively.
Conclusions: The T. cruzi OligoC-TesT showed high sensitivity and specificity on a diverse panel of biological samples. The
new tool is an important step towards simplified and standardized molecular diagnosis of Chagas disease.
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Introduction
Accurate diagnosis of Chagas disease, the most important
parasitic disease in the Americas [1], is challenging due to the
latent character of the infection. Following a brief acute phase,
infected individuals can progress to a lifelong chronic phase and
about 30% will eventually develop the typical cardiac and intestinal
complications that can be fatal [2]. Trypanosoma cruzi, the protozoan
pathogenic agent, is naturally transmitted by blood sucking
Triatominae bugs. Additional transmission routes include vertical
transmission from mother to child, transfusion with infected blood
and organ transplantation. Oral T. cruzi transmission by the
consumption of contaminated food is linked to localized outbreaks
of acute Chagas disease [3]. The T. cruzi species is genetically
heterogeneous and has been classified in two major phylogenetic
lineages, T. cruzi Ia n dT. cruzi II, of which the latter is subdivided in
5 sublineages (IIa to IIe). T. cruzi I predominates in endemic
countries north of the Amazon, whereas T. cruzi II is predominant
throughout the Southern Cone countries of South America. T. cruzi
I is associated with domestic and sylvatic transmission cycles, while
IIa and IIc seem to be restricted to sylvatic cycles and IIb, IId and
IIe to domestic cycles [4]. Both lineages are associated with cardiac
lesions in human infection, but it seems that digestive tract lesions
onlyoccurininfectionwithT.cruziII[5].T.cruziiscloselyrelated to
T. rangeli that is apparently harmless to man but shares the same
reservoir animals and vectors [6].
Acute infections, although rarely recognized because of the non-
specific clinical manifestations, can be diagnosed by parasitological
tests since the parasite load in the blood at that stage is generally
high enough. Chronic infections, on the contrary, are associated
with a very low parasite load in the blood and are therefore mainly
diagnosed by means of antibody detection tests. However,
antibody detection tests are liable to specificity problems due to
cross-reaction with antibodies induced by other parasites,
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recommended that specimens are tested in two or three different
immunodiagnostic tests, such as indirect immunofluorescence
(IIF), indirect hemagglutination (IHA) and enzyme-linked immuno
sorbent assays (ELISA). Furthermore, immunodiagnostic tests are
less useful in testing the effectiveness of treatment and congenital
infections. Xenodiagnosis is regularly used for parasite detection
but results of this invasive test are only available after 1 to 3
months and the method shows generally low sensitivity with
chronic infections [8]. Accurate tools to rapidly diagnose active
infections, to assess treatment efficacy and to determine the impact
of transmission control measures are needed. The introduction of
the polymerase chain reaction (PCR) to amplify specific DNA
sequences opened promising diagnostic perspectives. PCR has
been used to detect T. cruzi in the blood of chronic chagasic
patients [9], in congenital transmission [10], in patient follow-up
after treatment [11] and in disease reactivation after heart
transplantation [12]. Despite the reported high sensitivity and
specificity, the PCR technique is restricted to high-level equipped
laboratories. This is partly due to the laborious and time-
consuming detection of the PCR products. Amplicons are
generally detected by electrophoresis in agarose gel followed by
U.V. illumination in the presence of the carcinogenic ethidium
bromide. Quantitative real-time detection of PCR amplified T.
cruzi DNA has been developed [13] and offers major advantages
such as increased sensitivity, high-throughput analysis and single
tube formats. However, the technique is complex and expensive.
Besides the need for simplification of the DNA amplification assay,
standardization is a crucial requirement for moving molecular
tools towards patient diagnosis and disease control.
Oligochromatography (OligoC) provides a simple and rapid
one-step dipstick format for detection of PCR products (Coris
BioConcept, Gembloux, Belgium; Patent nu WO 2004/
099438A1) [14]. After the PCR step, the detection step takes
only 5 minutes and no other equipment than a water bath and
pipette are needed. Controls for the PCR reaction and the
chromatographic migration are incorporated in the assay. The
technique has already been developed for diagnosis of human
African trypanosomiasis [15], leishmaniasis [16], toxoplasmosis
[17], schistosomiasis [18] and severe acute respiratory syndrome
(SARS) [19], and high sensitivity and specificity were reported.
We here describe the development and phase I evaluation of a T.
cruzi PCR-Oligochromatography test (T. cruzi OligoC-TesT),
targeting a highly conserved satellite DNA sequence [20]. We
assessed the diagnostic accuracy of the assay on a broad spectrum of
biological samples from Chagas non-endemic and endemic control
persons, infected children, adults, reservoir animals and vectors.
Methods
Experimental samples
T. cruzi Y (lineage IIb) epimastigotes were grown in glucose-
lactalbumine-serum-hemoglobine (GLSH) medium [21] with 10%
fetal calf serum at 26uC. At day 3 post-inoculation, parasites were
counted in a Bu ¨rker counting chamber (Marienfeld, Germany).
Tenfold dilution series of parasites ranging from 10,000 parasites/
180 ml to 1 parasite/180 ml blood were made in human blood
freshly taken on EDTA from a healthy volunteer. Non-spiked blood
was used as negative control. Purified DNA from T. cruzi OPS21
Cl11, STC35R, IVV Cl3, X110/8, RN PCR 0 and VMV4,
belonging to lineage I, IIa, IIb, IIc, IId and IIe, respectively, was
obtained from the DNA reference bank at the Institute of Tropical
Medicine Antwerp (ITMA), Belgium. DNA from 25 different
Trypanosoma rangeli isolates (Table 1) and from Leishmania donovani,
Trypanosoma brucei gambiense, Mycobacterium tuberculosis, Schistosoma
mansoni and Plasmodium falciparum was obtained from other research
groups. DNA concentrations were measured in the Nanodrop ND-
1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wil-
mington, USA) and the DNA was stored at 220uC.
Biological samples
Ethical clearance for the study was obtained from the ethics
committee of the Faculty of Medicine, University of Chile,
Santiago, Chile. Written informed consent was given by the
patients or guardians and from non-diseased persons. Research on
biological samples from animals was conducted adhering to the
institution’s guidelines for animal husbandry.
Blood samples from Chagas non-endemic and endemic
controls. DNA extracts from blood of 20 confirmed T. brucei
gambiense infected persons from the Democratic Republic of the
Congo (DRC), 20 confirmed L. donovani infected persons from
Nepal and 20 confirmed P. falciparum infected persons from
Zambia were obtained from the collection of the Department of
Parasitology of the ITMA. Infections were confirmed by direct
parasite detection in blood or tissue aspirates. Blood samples from
48 Chagas endemic control persons were obtained at the blood
bank of the Clinical Hospital, University of Chile in 2004. Blood
bank samples were classified as not infected with T. cruzi if negative
in two different antibody detection tools (IIF and ELISA).
Blood samples from T. cruzi infected persons. 2m lw h o l e
blood from 6 children (0–10 years old) and 27 adults (.18 years old)
infected with T. cruzi were collected in Chile (region IV), between the
years 2000 and 2004. The blood was mixed with an equal volume of
6 M guanidine-HCl and 0.2 M EDTA, and 200 ml was subjected to
DNA extraction. Persons were considered as infected with T. cruzi if
positive in kDNA PCR amplifying the minicircle variable region
followed by Southern blot hybridization with a T. cruzi specific probe,
as described by Zulantay et al. [22]. For 20 of the 27 adult Chagas
disease patients, clinical, serological and xenodiagnosis data were
available. Six patients showed normal electrocardiogram (ECG)
results, 11 showed prolonged QTC syndrome and one showed sinus
tachycardia, while for 2 patients no ECG was done. All 20 patients
Author Summary
Chagas disease (American trypanosomiasis) is caused by
the protozoan parasite Trypanosoma cruzi and represents a
major public health problem in Latin America. Further-
more, growing human population movements extend the
disease distribution to regions outside the South American
continent. Accurate diagnosis is crucial in patient care and
in preventing transmission through blood transfusion,
organ transplantation, or vertical transmission from
mother to child. Routine diagnosis of Trypanosoma cruzi
infection generally is based on detection of the host’s
antibodies against the parasite. However, antibody detec-
tion tests are liable to specificity problems and are of
limited use in assessing treatment outcome and congen-
ital infections. The introduction of the polymerase chain
reaction (PCR) to amplify specific DNA sequences opened
promising diagnostic perspectives. Despite its reported
high sensitivity and specificity, broad use of the PCR
technique in diagnosis of Chagas disease is hampered by
its complexity and the lack of any standardization. We here
present the development and evaluation of the T. cruzi
OligoC-TesT, a simple and standardized dipstick format for
detection of PCR amplified T. cruzi DNA. The new tool is an
important step towards simplified and standardized
molecular diagnosis of Chagas disease.
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ELISA). All 20 patients were negative in xenodiagnosis but 5 showed
a positive result when the kDNA PCR was performed on the
xenodiagnosis specimens.
Biological samples from reservoir animals and
vectors. 200 ml blood from 2 Octodon degus and 5 Abrothrix
olivaceus rodents and the intestinal content from 14 Mepraia spinolai
bugs were collected. All animals originated from Las Chinchillas
National Reserve (Chile, region IV) and were classified as infected
with T. cruzi based on positive results in kDNA PCR followed by
Southern blot hybridization [22].
DNA extraction
DNA from T. cruzi Y culture was extracted with the QIAamp
DNA mini kit (Qiagen, Hilden, Germany). Spiked blood and
blood from the endemic control persons were extracted using the
QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). DNA
from blood of patients and animals was extracted with the EZNA
blood DNA kit (Omega Bioteck, Inc., Doraville, GA). Intestinal
content of the vectors was mixed with 200 ml PBS, boiled for
10 minutes and centrifuged at 10,000 g. The supernatant was
used as DNA template.
Primers and probes
An alignment of the internal control and target DNA, primers and
probes sequences is presented in Figure 1. Primers, probes and
internal control DNA were synthesized by Biomers.net (Ulm,
Germany).
Primers. 103 sequences of the 195 bp T. cruzi satellite DNA
(GenBank accession numbers AY519985 to AY520098) were
aligned using the ‘‘DNA man’’ software (Lynnon Corporation,
Quebec, Canada). The sense primer Tc-Sat-F 59-CACTCTC-
TGTCAATGTCTGTTTGCGTG-39 and anti-sense primer Tc-
Sat-R 59-GAAATTCCTCCAAGCAGCGGATA-39 were
designed targeting a conserved 81 bp sequence within the T.
cruzi satellite DNA. The anti-sense primer Tc-Sat-R was
biotinylated at the 59 end.
Internal control DNA. The internal control (IC) DNA
sequence (81 bp) is identical to the T. cruzi target sequence
except for a 20 bp central part. The IC central sequence was
designed with the same length and the same GC content as the T.
cruzi central sequence.
Probes. The T. cruzi detection probe (59-TGGACA-
CCAAACAACCC-39) and the IC detection probe (59-
AGGGTCTACTGGGTTACCTG-39) were designed to
hybridize the T. cruzi and IC central sequences respectively. The
detection probes were conjugated with gold particles using the
procedure described in patent WO 2004/099438A1 [14]. The T.
cruzi and IC migration control probes were synthesized with the
reverse complement sequence of the respective detection probes.
PCR amplification
The 50 ml PCR reaction mixture was prepared by adding 2.5 ml
sample DNA and 1 unit of Hot Star Taq polymerase (Qiagen,
Hilden, Germany) to 47.3 mlo fT. cruzi Ampli-Mix (Coris
Table 1. Code, origin, host, and amount of DNA detected by the T. cruzi OligoC-TesT of 25 T. rangeli isolates.
T. rangeli isolate Origin Host DNA detected by OligoC-TesT
SJMC2 Bolivia Tamandua tetradactyla Not detected at 1 ng
PARAMA31 Venezuela Myrmecophaga tridactyla Not detected at 1 ng
RPLA4 Venezuela Rhodnius prolixus Not detected at 1 ng
A4 Venezuela Homo sapiens Not detected at 1 ng
B28P1A06P1C1 Venezuela Rhodnius prolixus Not detected at 1 ng
B28V1A06P2C3 Venezuela Rhodnius prolixus Not detected at 1 ng
CAN AC Venezuela Canis lupus familiaris Not detected at 1 ng
C23 Colombia Rhodnius prolixus Not detected at 1 ng
C50 Colombia Rhodnius prolixus 1n g
Ev26 Colombia Aotus hivirgilus 1n g
R1271 Colombia Rhodnius prolixus 1n g
SJM30 Bolivia Tamandua tetradactyla 1n g
010 Panama Homo sapiens 1n g
P13 Venezuela Tamandua tetradactyla 1n g
RGB Venezuela Canis lupus familiaris 100 pg
B2 Venezuela Homo sapiens 100 pg
SJMC1 Bolivia Tamandua tetradactyla 100 pg
LEM2953 Guyana Bradypus tridactylus 100 pg
LEM2946 Guyana Saguinus midas 100 pg
LEM2947 Guyana Saguinus midas 100 pg
LEM2952 Guyana Tamandua tetradactyla 100 pg
LEM2963 Guyana Alouatta seniculus 10 pg
LDG Colombia Homo sapiens 10 pg
CAS3 Colombia Homo sapiens 10 pg
009 Panama Homo sapiens 10 pg
doi:10.1371/journal.pntd.0000450.t001
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contains all components to allow PCR amplification, the primers
Tc-Sat-F and Tc-Sat-R and the IC DNA at a concentration of
10
218 M. The commonly used dTTP was replaced by dUTP to
allow elimination of carry-over contamination with uracyl-DNA
N-glycosilase. An initial denaturation step at 94uC for 15 minutes
to activate the Hot Star Taq polymerase was followed by 40 cycles
of 94uC for 20 seconds, 65uC for 20 seconds and 72uC for
20 seconds, and a final extension at 72uC for 1 minute.
Amplification was carried out in 200 ml thin-wall PCR tubes
(Abgene, Epsom, United Kingdom) in a T3 thermocycler 48
(Biometra, Go ¨ttingen, Germany).
Oligochromatography
Principle. The T. cruzi Oligo-Strip construction and principle
is the same as the HAT-PCR-OC dipstick described by
Deborggraeve et al. [15] but a migration control line was added
to the test side. A schematic overview of the T. cruzi OligoC-TesT
principle is presented in Figure 2. The IC line and the migration
control lines determine whether the T. cruzi OligoC test is valid or
invalid. An invisible migration control line indicates an invalid
detection step, while an invalid PCR reaction is indicated by a
negative IC line in combination with a negative test line. The
latter may happen due to inhibitory factors in the extracted DNA.
The assay is repeated when the control lines indicate failure of
migration or of the PCR reaction. When a sample contains high
concentrations of T. cruzi DNA, competition between the T. cruzi
and the IC template DNA can result in an invisible IC control line
but now combined with a strongly visible T. cruzi test line. In this
case the test result is considered as a valid positive result.
Assay procedure. After PCR amplification the PCR product
is denaturated at 94uC for 30 seconds and transferred immediately
to ice. Forty microliters are mixed with an equal volume of
OligoStrip running buffer preheated at 55uC, followed by dipping
the T. cruzi Oligo-Strip into the solution. Test results are read after
5 minutes qualitatively. Whenever a test line appears that is visible
by naked eye, the test is considered positive. Once test results are
read the Oligo-Strips should not be stored for future reading as
background may appear after drying of the strip.
Results
Analytical sensitivity
The detection limit of the T. cruzi OligoC-TesT was evaluated
on three independent tenfold serial dilutions of T. cruzi strain Y
DNA in water containing 0.1 mg/ml acetylated bovine serum
albumin (BSA). The lower detection limit was consistently 1 fg
DNA per assay (Figure 3A) which is about 1/200 of the DNA
content of one parasite. The analytical sensitivity was also
evaluated on DNA extracted from three independent blood
sample series spiked with decreasing numbers of living T. cruzi
epimastigotes. The assay was able to detect 1 parasite in a 180 ml
blood sample (Figure 3B), while non-spiked control blood samples
always remained negative.
Analytical specificity
The analytical specificity of the assay was evaluated on tenfold
serial dilutions of DNA from T. cruzi strains representative for the
6 different lineages and on DNA from relevant non target
pathogens. The T. cruzi OligoC-TesT was able to detect 1 fg DNA
of the strains X110/8 (lineage IIc), RN PCR O (IId) and VMV4
(IIe), 10 fg DNA of the strains STC 35R (IIa) and IVV Cl3 (IIb),
and 1 pg DNA of the strain OPS21 (I). Negative test results were
observed with 5 ng purified DNA per test of L. donovani, T. brucei
gambiense, M. tuberculosis, S. mansoni and P. falciparum. To assess the
level of T. rangeli detection by the T. cruzi OligoC-TesT, tenfold
serial dilutions of purified DNA from 25 different T. rangeli isolates
were tested (Table 1). Four T. rangeli isolates could be detected at a
DNA concentration of 10 pg per assay, 13 at a DNA
concentration of 100 pg or 1 ng, while 8 isolates remained
negative when tested at 1 ng DNA per assay.
Specificity on Chagas non-endemic and endemic control
blood samples
Negative results were observed when testing DNA extracts from
blood of 20 T. brucei gambiense infected persons from DRC, 20 L.
donovani infected persons from Nepal, 20 P. falciparum infected
persons from Zambia, and 48 Chagas endemic control blood
samples from Chile (Table 2). Hence, the specificity of the assay on
60 Chagas non-endemic and 48 endemic control blood samples
was 100% with a 95% confidence interval [CI] scored by Wilson’s
method of 96.6% to 100% [23].
Sensitivity on T. cruzi infected patients, vectors and
reservoir animals
The diagnostic accuracy of the T. cruzi OligoC-TesT was tested
in 2007 on biological samples from 6 T. cruzi infected children and
27 infected adults, 2 infected O. degus rodents, 5 infected A. alivaceus
rodents and 14 infected M. spinolai bugs (Table 2). All samples
showed a positive test result except for 2 blood samples from
children. Hence, the test showed a sensitivity of 66.7% (95% CI:
30%–90.3%), 100% (87.5%–100%), 100% (95% CI: 64.6%–
Figure 1. Presentation of the target DNA, primers and probes sequences. Alignment of the internal control (IC) DNA sequence and the T.
cruzi OligoC-TesT DNA target sequence (T.c.) within the satellite DNA (consensus sequence of GenBank accession numbers AY519985 to AY520098).
The forward primer Tc-Sat-F (1), the biotinylated (Biot) reverse primers Tc-Sat-R (2), the T. cruzi detection probe (3) and the IC detection probe (4) are
shown.
doi:10.1371/journal.pntd.0000450.g001
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infected children, adults, rodents and vectors, respectively. The
two OligoC-TesT negative blood samples showed invalid results in
two independent repetitions. Therefore, DNA was ethanol
precipitated and washed as described elsewhere [15]. The purified
DNA samples were retested in T. cruzi OligoC-TesT and valid
negative test results were observed.
Discussion
Antibody detection is routinely used for diagnosis of Chagas
disease but suffers from specificity problems because of cross-
reactivity with antibodies against other infectious agents such as
Leishmania spp. and T. rangeli. Furthermore, immunodiagnosis is
less useful in cure assessment after treatment and in diagnosis of
congenital transmission. Xenodiagnosis is cumbersome, time
consuming and invasive. Molecular detection of the parasite by
the PCR technique is able to overcome most of these drawbacks
since high sensitivity and specificity is combined with detection of
DNA as surrogate for parasite detection. Despite the major
advantages, PCR is still restricted to research applications and did
not enter many diagnostic laboratories yet, which is mainly due to
the complexity of the technique. Furthermore, the numerous in
house diagnostic PCR assays and the neglect of any standardiza-
tion hamper this promising technique to occupy a major position
in clinical diagnosis. Next to patient management, PCR can play
an important role as an accurate surrogate for parasite detection in
epidemiological studies on reservoir animals and vectors.
In this study a molecular dipstick assay for simple, rapid and
standardized detection of T. cruzi DNA was developed and
evaluated. The T. cruzi OligoC-TesT consists of PCR amplifica-
tion of a short sequence within the T. cruzi satellite DNA followed
Figure 2. Schematic overview of the T. cruzi OligoC-TesT. Polymerase chain reaction (PCR) amplification of a sample containing T. cruzi DNA (1)
is performed using a PCR mix containing single-stranded internal control (IC) template (2). The IC sequence is the same as the target sequence within
the T. cruzi satellite DNA but with a specific internal sequence (dotted line). Both templates are amplified with the same primers of which the reverse
primer is biotinylated (N). When the PCR and subsequent denaturation is completed, the PCR product solution contains single-stranded T. cruzi and IC
DNA (3), and is mixed with an equal volume of migration buffer preheated at 55uC. The T. cruzi Oligo-Strip is dipped into the mixture and test results
are read after 5 minutes migration at 55uC (4). During migration, the solution takes up the gold-labelled (#) detection probes. The T. cruzi detection
probes (5) at the test side and the IC detection probes (6) at the control side hybridise with their respective amplicons. The biotinylated PCR products
accumulate on the neutralite avidin lines at both sides of the dipstick and the T. cruzi and IC amplicons are visualized by their respective detection
probes (7). In case of a negative sample, only the IC amplicon is present and visualized at the control side of the dipstick (8). The excess of detection
probes migrate further and hybridise on the complementary probes coated at both sides of the dipstick as a control for migration (9).
doi:10.1371/journal.pntd.0000450.g002
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detection step is performed in 5 minutes and the only equipment
needed is a pipette and water bath. The lower detection limits of
the assay are 1 fg of purified T. cruzi strain Y DNA and 1 parasite
in a 180 ml blood sample. This is similar to the detection limits of
the primers Tcz1/Tcz2 and Diaz1/Diaz2 targeting the same
195 bp satellite DNA as reported by Moser et al. [24] and Diaz et
al. [25], respectively. However, when we tested serial dilutions of
DNA from T. cruzi strains representative for the 6 lineages we
observed a 100 to 1000 times lower sensitivity on the T. cruzi strain
of lineage I compared to the strains of lineage II. The lower
sensitivity on T. cruzi lineage I is probably due to the lower copy
number of the satellite repeats in lineage I as reported by Elias et
al. [26]. This is confirmed by the fact that Diaz et al. also observed
a lower sensitivity of their primers on DNA from T. cruzi I strains
[25]. The test showed a positive signal when tested on purified
DNA from T. rangeli. To assess the level of cross-reaction, serial
dilution series of DNA of 25 different T. rangeli isolates were tested.
Four of the 25 isolates could be detected at 10 pg DNA per test
which is 10 times more than the required DNA of T. cruzi lineage I
and 100 to 1000 times more than T. cruzi lineage II. Fourteen T.
rangeli isolates required a higher amount of DNA to be detectable
with the T. cruzi OligC-TesT and 8 remained negative at 1 ng
DNA per assay. This is in contrast with Ochs et al. [27] and
Virreira et al. [10] who reported no amplification of T. rangeli
DNA by the Tcz1/Tcz2 primers. However, these authors used
only one T. rangeli isolate and one DNA concentration. The
observed cross-reaction with T. rangeli is not surprising since the
Figure 3. Analytical sensitivity of the T. cruzi OligoC-TesT. The upper and lower line are the migration control and the T. cruzi test line
respectively. A. Test results on a serial dilution of T. cruzi strain Y DNA in water containing 0.1 mg/ml acetylated bovine serum albumine (BSA).
Dipsticks 1–10: 1 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, 0.1 fg, 0.01 fg and 0 fg per assay. B. Test results on a serial dilution of T. cruzi
epimastigotes in naı ¨ve human blood. Dipsticks 1–6: 10,000; 1,000; 100; 10; 1 and 0 parasites in 180 ml blood.
doi:10.1371/journal.pntd.0000450.g003
Table 2. Diagnostic accuracy of the T. cruzi OligoC-TesT on biological samples from Chagas non-endemic controls and endemic
controls and from T. cruzi infected persons, reservoir animals and vectors.
Biological samples # Positive in T. cruzi OligoC Specificity (95% CI) Sensitivity (95% CI)
Non-endemic controls
HAT patients (DRC) 20 0 100% (83.9%–100%)
LEI patients (Nepal) 20 0 100% (83.9%–100%)
MAL patients (Zambia) 20 0 100% (83.9%–100%)
Endemic controls (Chile)
Blood bank samples 48 0 100% (92.6%–100%)
Chagasic patients (Chile)
Children 6 4 66.7% (30%–90.3%)
Adults 27 27 100% (87.5%–100%)
Infected animals (Chile)
Octodon degus 22 100% (34.2%–100%)
Abrothrix olivaceus 55 100% (56.6%–100%)
Infected vectors (Chile)
Mepraia spinolai 14 14 100% (78.5%–100%)
Notes:
# number of samples.
95% CI 95% confidence interval (by Wilson’s method).
DRC Democratic Republic of the Congo.
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reported that the number of repeats of the 195 bp satellite DNA is
far lower in T. rangeli than in T. cruzi, which might explain the
higher detection threshold of the assay for T. rangeli. The variable
T. rangeli detection levels are probably due to variable copy
numbers of the satellite repeats within the T. rangeli population, as
described for T. cruzi [26]. However, a parasitaemia of 10,000 T.
rangeli parasites per ml of blood in human is unlikely since several
studies reported no or very low T. rangeli multiplication in
mammalian host cells [29,30].
The specificity of the T. cruzi OligoC-TesT was estimated at
100% on blood samples from 60 Chagas non-endemic and 48
endemic control persons. Sensitivities of 93.9% on 33 infected
patients and of 100% on 7 infected rodents and 14 infected vectors
were observed. The high sensitivity on blood samples from adults
is encouraging given the general low parasitaemia in the blood of
such patients. However, we used a kDNA PCR followed by
Southern blot as the main reference test instead of immunodiag-
nosis, that is currently the standard diagnostic technique for
chronic Chagas disease. All 20 adult patients for which additional
diagnostic test results were available showed positive immunodi-
agnostic test results but were negative in conventional xenodiag-
nosis, indicating the high sensitivity of PCR based parasite
detection. Further evaluations are needed to estimate the
diagnostic accuracy of the test on chronic Chagasic patients
diagnosed on the basis of immunodiagnostic tools alone. The
negative results on the two blood samples from children are
unexpected since parasite loads are generally higher in children
than in adults. The two samples showed initially invalid T. cruzi
OligoC-TesT results, indicating inhibition of the PCR reaction.
Therefore, the DNA was precipitated, washed and retested with
the T. cruzi OligoC-TesT where after the tests became valid but
negative. The DNA might have been lost during the multiple
purification steps. The test showed high sensitivity on reservoir
animals and vectors, which is promising regarding the coexistence
of different T. cruzi lineages, including lineage I, at the collection
site as reported by Rozas et al. [31].
In conclusion, the diagnostic accuracy on this diverse panel of
biological samples indicates the potential of the T. cruzi OligoC-
TesT. Further phase II and III evaluation studies are needed to
assess the diagnostic sensitivity and specificity of the test on human
target populations in different endemic regions. Persons with
potentially cross-reacting diseases such as leishmaniasis should be
included in the control group during future phase II evaluations.
This new tool is a first step towards low-tech and user-friendly
molecular diagnostics for T. cruzi detection. Besides the simplifi-
cation, presentation of the T. cruzi OligoC-TesT as a self-
containing kit with ready-to-use PCR mix and dipsticks offers
excellent prospects for PCR standardization. Standardization of
the PCR technique is crucial for its implementation as a reference
parasite detection test for diagnosis and clinical studies. Chagas
disease is routinely diagnosed by antibody detection but a simple
and standardized PCR format can play an important role in
situations were the use of immunodiagnosis is limited, such as
congenital Chagas disease, patient follow-up after treatment and
disease re-activation after organ transplantation. An additional
potential niche for the T. cruzi OligoC-TesT may be patients with
acute Chagas disease but negative test results in direct microscopy
and patients with chronic Chagas disease but inconsistent or
borderline immunodiagnostic test results. Isothermal amplification
of the parasite’s DNA through novel methods such as the loop
mediated isothermal amplification (LAMP) [32] and the nucleic
acid sequence based amplification (NASBA) [33] might further
simplify the assay. Furthermore, standardized PCR formats to
discriminate the 6 lineages of T. cruzi would be most welcome,
since accurate lineage discrimination is important for disease and
vector control programmes [34]. Additional standardization of the
sampling procedures and DNA extraction is needed as well.
In conclusion, the T. cruzi OligoC-TesT represents a simplified
and standardized PCR format for T. cruzi detection in biological
samples. The innovative assay bears clear potential as a simplified
molecular diagnostic tool for Chagas disease in midlevel-equipped
laboratories.
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